AIAI Holdings Corporation Class A Common Stock

AIAI Holdings' MediGuide Enters the State-of-the-Art Medicine Market With AI-Driven Innovation

2026-07-14 10:40:00

Leveraging Advanced Diagnostics and Screenings to Provide Personalized Proactive Care DALLAS, TX / ACCESS Newswire / July 14, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its portfolio company, MediGuide, has launched a state of the art (SOTA) precision healthcare solution that combines advanced medical intelligence, expert clinical review, and AI-enabled diagnostic support to enable more personalized, data-driven medical decision-making. The launch represents another milestone in MediGuide's innovation roadmap and reflects AIAI Holdings' strategy of supporting portfolio companies that responsibly integrate advanced technologies into scalable, real-world business applications.

NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner

2026-07-09 07:00:00

New agreement is a significant commercial milestone and the Company's first with its contract research organization partner Agreement expands NetraMark's portfolio of AI-driven projects in central nervous system (CNS) disorders TORONTO, July 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine, today announced that it signed a new contract to analyze a phase 2 neurodegeneration dataset through its established contract research organization (CRO) partnership. “This contract is an important commercial milestone for NetraMark because it represents our first contract flowing through a CRO, rather than directly with a biopharmaceutical company,” said George Achilleos, Chief Executive Officer of NetraMark.

AIAI Holdings' Constellation Network Launches Gate AI: Real-Time Security for AI Applications

2026-07-08 08:30:00

AI security gateway delivering prompt injection protection, token cost reduction, and verified auditability through Constellation Digital Evidence DALLAS, TX / ACCESS Newswire / July 8, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its portfolio company, Constellation Network has publicly launched Gate AI. Gate AI is a security layer that sits between an AI application and the model, protecting requests in real time.

AIAI Holdings' MediGuide Launches Digital Platform

2026-07-01 08:30:00

Digital Transformation Initiative Establishes Operational Foundation for Innovation in Diagnostics, Prevention and Precision Medicine DALLAS, TX / ACCESS Newswire / July 1, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its portfolio company, MediGuide International, has launched a new enterprise digital platform. MediGuide's digital platform is an API-first, interoperable layer that connects insurers, payors, and digital health partners to MediGuide's clinical services, Medical Second Opinion, virtual urgent/primary/behavioral/specialty care, and chronic condition programs, through a single, configurable integration.

NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company

2026-06-29 07:00:00

TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that it has signed a new agreement with a biopharmaceutical company developing a late-stage central nervous system therapy.

AIAI Holdings Unveils AI Integration Playbook for Portfolio Companies

2026-06-23 08:30:00

Strategic framework meets businesses where they are today, identifying Transformational AI enabled value creation opportunities DALLAS, TX / ACCESS Newswire / June 23, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announces its strategic and comprehensive post-acquisition AI integration framework, pursuant to which it will identify, design, and implement AI-enabled value creation opportunities across the Company's portfolio businesses. This disciplined, repeatable playbook is expected to move portfolio companies from initial operational assessment to active Transformational AI implementation, fundamentally redefining their financial potential.

Rochon Family Executes Strategic Purchase of AIAI Holdings Shares

2026-06-18 08:30:00

DALLAS, TX / ACCESS Newswire / June 18, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI to enhance portfolio performance, today announced that John P. Rochon, Chairman of Ai² and entities controlled by the family of Mr.

NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026

2026-06-09 07:00:00

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET.